CHOP (Cyclophosphamide, Hydroxyldaunomycin [Doxorubicin], Oncovin [Vincristine] and Prednisone), in combination with Rituximab (R-CHOP) is the current standard of care (SOC) for DLBCL [13], [14]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.